LUCD

Lucid Diagnostics (LUCD)

Lucid Diagnostics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:LUCD

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/03/10	22 : 01	PR Newswire (US)	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/03/06	06 : 45	PR Newswire (US)	Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/03/06	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/03/05	20 : 36	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/03/04	22 : 25	PR Newswire (US)	Lucid Diagnostics Announces $15.3 Million Registered Direct Offering	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/03/04	22 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/03/04	21 : 56	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/27	22 : 31	PR Newswire (US)	Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/25	22 : 31	PR Newswire (US)	Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/22	07 : 56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/22	06 : 58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/22	06 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/20	22 : 31	PR Newswire (US)	Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/18	22 : 30	PR Newswire (US)	PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/14	03 : 38	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/06	22 : 57	PR Newswire (US)	Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/01	06 : 49	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/02/01	06 : 46	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:LUCD	Lucid Diagnostics Inc
2025/01/13	21 : 56	PR Newswire (US)	Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/12/23	22 : 01	PR Newswire (US)	Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/12/21	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/12/19	22 : 01	PR Newswire (US)	Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/12/11	22 : 01	PR Newswire (US)	Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/12/07	06 : 10	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/12/03	22 : 01	PR Newswire (US)	Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/11/30	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/11/20	21 : 56	PR Newswire (US)	Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/11/19	07 : 27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/11/18	22 : 15	PR Newswire (US)	Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum	NASDAQ:LUCD	Lucid Diagnostics Inc
2024/11/14	22 : 01	PR Newswire (US)	PAVmed Provides Business Update and Third Quarter 2024 Financial Results	NASDAQ:LUCD	Lucid Diagnostics Inc